Medpace Holdings Inc
$ 442.20
-0.62%
24 Feb - close price
- Market Cap 12,550,204,000 USD
- Current Price $ 442.20
- High / Low $ 452.01 / 438.87
- Stock P/E 28.96
- Book Value 16.18
- EPS 15.27
- Next Earning Report 2026-04-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.16 %
- ROE 0.70 %
- 52 Week High 628.92
- 52 Week Low 250.05
About
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Analyst Target Price
$486.92
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-09 | 2025-10-22 | 2025-07-21 | 2025-04-21 | 2025-02-10 | 2024-10-21 | 2024-07-22 | 2024-04-22 | 2024-02-12 | 2023-10-23 | 2023-07-24 | 2023-04-24 |
| Reported EPS | 4.67 | 3.86 | 3.103 | 3.67 | 3.6813 | 3.01 | 2.75 | 3.2 | 2.46 | 2.22 | 1.93 | 2.27 |
| Estimated EPS | 4.18 | 3.53 | 2.99 | 3.0775 | 3.1167 | 2.78 | 2.54 | 2.47 | 2.22 | 2.05 | 1.91 | 1.8 |
| Surprise | 0.49 | 0.33 | 0.113 | 0.5925 | 0.5646 | 0.23 | 0.21 | 0.73 | 0.24 | 0.17 | 0.02 | 0.47 |
| Surprise Percentage | 11.7225% | 9.3484% | 3.7793% | 19.2526% | 18.1153% | 8.2734% | 8.2677% | 29.5547% | 10.8108% | 8.2927% | 1.0471% | 26.1111% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-27 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 3.92 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MEDP
2026-02-23 17:32:42
Medpace Holdings Inc (MEDP) experienced a 3.61% drop in its stock price on February 23rd, reaching an intraday low of $436.98. Despite this decline, analyst forecasts suggest a potential upside of 11.50% with an average target price of $487.70, and GuruFocus estimates a 19.14% upside based on its fair value calculations. The consensus brokerage recommendation for MEDP is currently "Hold."
2026-02-23 17:32:42
Several stocks, including Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health, experienced declines after the Trump administration announced new global tariffs using the Trade Act of 1974. This move reintroduced trade policy uncertainty in the market, impacting companies reliant on international supply chains. Investors are now assessing the potential effect of these tariffs on corporate earnings and worldwide economic activity.
2026-02-20 07:59:22
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Medpace Holdings, Inc. on behalf of its stockholders. The investigation follows Medpace's Q4 2025 earnings report, which revealed a lower-than-expected book-to-bill ratio due to increased cancellations, contrasting with prior optimistic statements. Medpace shares fell by approximately 15.9% after the disclosure, prompting the law firm to encourage affected investors to contact them.
2026-02-20 00:26:42
Bragar Eagel & Squire, P.C. is investigating Medpace Holdings, Inc. following a significant drop in its stock price and discrepancies in reported book-to-bill ratios. Concerns arose after Medpace disclosed a lower-than-expected book-to-bill ratio of 1.04, with the CEO attributing it to cancellations, contradicting earlier positive statements. The firm is inviting investors who suffered losses to contact them to discuss potential legal claims against Medpace.
2026-02-19 23:36:27
Bragar Eagel & Squire, P.C. has launched an investigation into Medpace Holdings, Inc. (MEDP) regarding potential violations of federal securities laws following a 15.9% stock price drop. While the company's Q4 2025 earnings exceeded expectations, concerns arose regarding a book-to-bill ratio miss and the highest level of project cancellations in over a year.
2026-02-19 22:26:42
Bragar Eagel & Squire, P.C. is investigating potential claims against Medpace Holdings, Inc. following a significant drop in its stock price. This investigation comes after Medpace reported Q4 2025 earnings with a lower-than-expected book-to-bill ratio and higher cancellations, contradicting previous optimistic statements from the CEO. Stockholders who suffered losses are encouraged to contact the firm to discuss their legal rights regarding potential violations of federal securities laws.
